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a  b  s  t  r  a  c  t
Bovine  leukemia  virus  (BLV)  is  associated  with  enzootic  bovine  leukosis  and  is  closely  related  to  human
T  cell  leukemia  virus  (HTLV).  The  cytotoxic  T  lymphocyte  (CTL)  plays  a key  role  in  suppressing  the  pro-
gression  of disease  caused  by BLV.  T and  B cell  epitopes  in  BLV  have  been  studied,  but  CD8+ CTL epitopes
remain  poorly  understood.  We  used  a  library  of  115  synthetic  peptides  covering  the  entirety  of  the Env
proteins  (gp51  and  gp30),  the Gag  proteins  (p15,  p24, and  p12),  and the Tax  protein  of BLV to identify
11  novel  CD8+ T cell  epitopes  (gp51N5,  gp51N11,  gp51N12,  gp30N5,  gp30N6,  gp30N8,  gp30N16,  tax16,
tax18,  tax19,  and tax20)  in  four  calves  experimentally  infected  with  BLV.  The  number  of CD8+ T  cell
epitopes  that  could  be identiﬁed  in  each  calf  correlated  with  the BLV  proviral  load.  Interestingly,  among
the  11 epitopes  identiﬁed,  only  gp51N11  was  capable  of inducing  CD8+ T cell-mediated  cytotoxicity  in
all  four  calves,  but  it is not  a suitable  vaccine  target  because  it shows  a high  degree  of polymorphism
according  to the  Wu–Kabat  variability  index.  By  contrast,  no  CTL  epitopes  were  identiﬁed  from  the Gag
structural  protein.  In addition,  several  epitopes  were  obtained  from  gp30  and  Tax,  indicating  that  cellular
immunity  against  BLV  is strongly  targeted  to these  proteins.  CD8+ CTL  epitopes  from  gp30 and  Tax  were
less  polymorphic  than epitopes  from.  Indeed,  peptides  tax16,  tax18,  tax19, and  tax20  include  a  leucine-
rich  activation  domain  that encompasses  a transcriptional  activation  domain,  and  the  gp30N16  peptide
contains  a proline-rich  region  that  interacts  with  a protein  tyrosine  phosphatase  SHP1 to regulate  B  cell
activation.  Moreover,  at least  one  CD8+ CTL  epitope  derived  from  gp30  was  identiﬁed  in each  of  the  four
calves.  These  results  indicate  that  BLV  gp30  may  be  the  best candidate  for the development  of  a  BLV
vaccine.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Bovine leukemia virus (BLV) is a member of the family Retro-
iridae that the causative agent of enzootic bovine leukosis (EBL),
hich is the most common neoplastic disease of cattle and is closely
elated to human T cell leukemia virus (HTLV) [1,2]. BLV expresses
he gag, pol,  and env genes, which are both essential and common
o retroviruses and are necessary for the production of infectious
irions [3]. The gag gene of BLV is translated as the precursor Pr70
ag and is processed into three mature proteins: p15 is the matrix
rotein, p24 is the most abundant capsid protein, and p12 is the
ucleocapsid protein [3,4]. The BLV env gene encodes a mature sur-
ace glycoprotein (gp51) and a transmembrane protein (gp30) [3].
∗ Corresponding author. Tel.: +81 48 462 4408; fax: +81 48 462 4399.
E-mail address: aida@riken.jp (Y. Aida).
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
gp51 and gp30 are directly involved in infectivity events such as
receptor recognition and membrane fusion [5]. Unlike other retro-
viruses, BLV encodes at least two  regulatory proteins, Tax and Rex.
Tax is a key contributor to the oncogenic potential, as well as a key
protein involved in the replication of the virus [1,2,6,7].
The CD8+ cytotoxic T lymphocytes (CTLs) mediate cellular
immunity by killing infected host cells and by producing cytokines
that can inhibit viral replication [8–10]. The major histocompat-
ibility complex (MHC) system in cattle is known as the bovine
leukocyte antigen (BoLA) system, and is strongly involved in the
subclinical progression of BLV infection [10,11]. MHC  molecules are
grouped into two  classes (I and II) that are highly polymorphic. The
1 and 2 domains of MHC  class I form a peptide binding groove
that accommodates antigen-derived peptides and presents them
to CD8+ T cells [10–12]. The binding of peptides to MHC  class I pro-
teins is the most selective event in antigen presentation to CD8+ T
cells [13].
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Cellular immunity is induced during natural BLV infection and
lays a role in protecting hosts from BLV infection [9,14–16]. Previ-
us studies postulated that cellular immunity against BLV antigens
ontributes to the suppression of BLV replication, thereby leading
o the delay in disease progression [9,14–22]. However, in these
revious studies, only a small number of peptides corresponding
o selected regions of the BLV Env and Tax proteins were used
o characterize CD4+ and CD8+ T cell epitopes for BLV. Here, we
dentiﬁed CD8+ T cell-restricted epitopes for BLV antigens as fol-
ows: (i) First, a library of 115 overlapping peptides covering the
ntirety of the Env proteins (gp51 and gp30), the Gag proteins
p15, p24, and p12), and the Tax protein was generated; (ii) Four
alves with deﬁned BoLA class I genotypes were experimentally
nfected with the amount of BLV taken from the same individual at
he same time; (iii) Mapping of the CD8+ T cell epitopes was  per-
ormed by the water-soluble tetrazolium salt (WST-8) assay using
he synthetic peptide library and CD8+ T cells were took from the
our BLV-infected calves; (iv) CD8+ T cell epitopes that induced
ig. 1. Synthetic peptides of 20-mer overlapping peptides corresponding to the Gag (p15
ere  made against each mature peptide encoded and expressed by genes in env, gag, and 
ccession no. EF600696), and Tax (GenBank accession no. EF600696) were reported. (A)
ool,  name, sequence and amino acid positions of peptide are shown in column (left to righ
cids  in length; and c18 amino acids in length.2015) 7194–7202 7195
proliferation in the initial screening were tested for their ability
to induce CD8+ T cell cytotoxicity in a non-radioactive cytotoxicity
assay; (v) The conservation of amino acids in CD8+ CTL epitopes was
analyzed by the Wu–Kabat variability index; and (vi) the expres-
sion of these epitopes by cattle with different BLV proviral loads is
described. These results may  help to select the best candidates for
synthetic peptide vaccine against BLV infection.
2. Materials and methods
2.1. Synthetic peptides
A series of 20-mer peptides overlapping by 10 amino acids were
designed based on the reported sequences of each mature peptide
encoded and expressed by genes in env, gag, and tax.  All of pep-
tides were synthesized and puriﬁed to >70% purity (Sigma). These
peptides are divided into 23 pools that were suspended in 80%
dimethylsulfoxide (DMSO) (Fig. 1).
, p24, and p12), Env (gp51 and gp30) and Tax proteins. These overlapping peptides
tax,  which sequences of BLV Gag (GenBank accession no. LC057268), Env (GenBank
 Schematic representation of BLV genome organization and viral proteins. (B) The
t). The pool contains ﬁve individual peptides. a15 amino acids in length; b19 amino
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.2. Experimental animals
Four BLV-negative Japanese Black calves (6–8-months-old)
ere experimentally challenged intravenously with blood con-
aining a proviral load of 4 × 107 proviral copies per 105
ells, as determined by the BLV-coordination of common
otifs-quantitative real-time polymerase chain reaction-2 (BLV-
oCoMo-qPCR-2) assay from BLV-infected Holstein-Friesian cattle
Table 1). This study was approved by the Animal Ethical Commit-
ee and the Animal Care and Use Committee of the Animal Research
enter, Hokkaido Research Organization (approval number 1302).
.3. Ampliﬁcation, cloning, and DNA sequencing of BoLA class I
RNAs were extracted from peripheral blood mononuclear
ells (PBMCs) obtained from each of experimantal calves and
ere reverse-transcribed into cDNA to obtain BoLA class I heavy
hain cDNA clones. cDNAs were ampliﬁed by PCR using primers
oLA 1F (5′-ATGCGAGTYATGGGGCCGCGAGCCC-3′) and BoLA 1R
5′-TCAMMCTTTAGGAACYGTGAGA-3′). The PCR products were
ubcloned into the pGEM-T easy vector (Promega). The sequences
ere analyzed using softwares, Sequencher ver. 4.0.5 (Gene Codes),
nd Genetyx ver. 10, software (Genetyx).
.4. Measurement of the BLV proviral load and anti-BLV
ntibodies
The BLV proviral load was measured using the BLV-CoCoMo-
PCR-2 method [23–26]. An anti-BLV antibody ELISA kit (JNC) was
sed according to the manufacturer’s instructions.
.5. Preparation of PBMCs and CD8+ T lymphocytes
PBMCs were separated according to the method of Miyasaka and
runka [27]. CD8+ T cells were puriﬁed using the 7C2B monoclonal
ntibody (MAb) (mouse anti-bovine CD8; VMRD) and anti-mouse
gG MAb  by the MACS System (Miltenyi Biotech). The CD8+ T
ymphocyte-depleted PBMCs were used as the CD8− T cells in this
tudy.
.6. WST-8 assay
The cell proliferation response against peptides was performed
y WST-8 assay [44]. It is a determination of cell viability in cell
roliferation that was reduced by dehydrogenase activities in cells
o give a yellow-color formazan dye, which was soluble in the
issue culture media. The amount of the formazan dye, generated
y the activities of dehydrogenases in cells, was directly propor-
ional to the number of living cells. Antigen-presenting cells (APCs)
ere prepared by treating CD8− T cells with 50 g/ml mitomycin C
able 1
apanese black calves examined in the studya.
Animal no. Proviral loadb
(CoCoMo-qPCR-2)
Breed Age (month) Sex 
A-JB 72 Japanese black 6 ♀ 
B-JB  58,501 Japanese black 7 ♂ 
C-JB  67,729 Japanese black 6 ♀ 
D-JB  76,839 Japanese black 8 ♂ 
a Blood samples (used for DNA and serum isolation) were collected for 10 weeks after 
b Proviral load (expressed as the number of copies of provirus per 105 peripheral blood
c White blood cells (WBCs) were measured at a single time point in all calves during th
d Peripheral blood lymphocytes (PBLs) were measured at a single time point in all calv
e BoLA class1 alleles are according to the BoLA nomenclature committee of the IPD–M
hich  is identical to the previously reported allele, BoLA-N*02604, D-JB carried a nove
GenBank accession no. LC055986) which is identical to the previously reported allele, Bo
lone  sequences using the pGEM®-T Easy Vector System. The allele was considered one o
f ELISA (enzyme-linked immunosorbent assay) to detect anti-BLV antibodies was  perfo2015) 7194–7202
(Sigma) for 60 min. APCs (2 × 106 cells/ml) and CD8+ T cells (2 × 106
cells/ml) were mixed in the presence of either peptide pool contain-
ing individual peptides at 20 M,  20 M positive peptide, or 80%
DMSO (negative control) at once, and were co-incubated at 37 ◦C
in a total volume of 110 l of cell medium. After 109 h of incuba-
tion, 10 l of WST-8 solution (Dojindo Molecular Technologies) was
added to each well, and then the cells were incubated for 4 h. The
microplate was read at an optical density (OD) of 450 nm.
2.7. CytoTox96 non-radioactive cytotoxicity assay
The CD8+ T cells cytotoxicity was performed by non-radioactive
cytotoxicity assay. It is a colorimetric alternative to 51Cr release
cytotoxicity assays. It quantitatively measures lactate dehydroge-
nase (LDH), a stable cytosolic enzyme that is released upon cell lysis.
Released LDH in culture supernatant is measured with a 30 min
coupled enzymatic assay, which results in the conversion of a tetra-
zolium salt (INT) into a red formazan product. The amount of color
formed is proportional to the number of lysed cells. Effector cells
(CD8+ T cells; 1 × 107 cells/50 l or 2 × 107 cells/50 l) were plated
in the experimental wells to measure spontaneous LDH release by
effector cells. Meanwhile, different concentrations of peptide were
added to the experimental wells, and target cells (PBMCs; 1 × 106
cells/50 l) were added to the experimental wells and the wells
measuring minimum (spontaneous) and maximum LDH release
and mixed at once. The microplate was  incubated for 48 h that
the effector cells were sufﬁciently activated by peptide at 37 ◦C.
Ten l of Lysis solution was added to the maximum LDH release
wells 45 min prior to the end of incubation period. After incuba-
tion, 50 l of supernatant was transferred from each well into a
fresh microplate for the enzymatic assay. Next, 50 l of the recon-
stituted substrate mix  was  added to each well and incubated at
room temperature for 30 min. Finally, 50 l of stop solution was
added and was  recorded the absorbance at 492 nm after 45 min
incubation. The percent cytotoxicity was calculated as follows:
Percent cytotoxicity
= experimental − effector spontaneous − target spontaneous
target maximum − target spontaneous
× 100
2.8. Statistical analysisThe conservation of epitopes was analyzed by Wu–Kabat vari-
ability index [28]. The function program in Microsoft Excel was  used
to conduct F-tests and t-tests for all results of cytotoxicity.
WBCsc (cells/l) PBLsd (cells/l) BoLA class 1e Allele Antibodies
to BLVf
7480 4520 BoLA-N*02604 +
13400 8650 BoLA-N*02702 +
13500 9250 BoLA-N*02604 +
14100 8820 BoLA-N*02701 +
the ﬁrst inoculation.
 mononuclear cells) was  evaluated using CoCoMo-qPCR-2.
e experiment.
es during the experiment.
HC database, calves A-JB and C-JB carried allele (GenBank accession no. LC055984)
l allele, BoLA-N*02701 (GenBank accession no. LC055985), and B-JB carried allele
LA-N*02702. The amino acid sequences of BoLA class were determined from cDNA
f the predominantly expressed types in each experiment animal.
rmed using the BLV ELISA kit + BLV positive serum.
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. Results
.1. Preparation of synthetic peptides and BLV-infected
xperimental calves
To characterize CD8+ T cell epitopes for BLV, previous studies
15,20,22,29] used a small number of peptides derived from por-
ions of the Env and Tax proteins. To conduct a more extensive
creen for CTL epitopes, we prepared a library of 115 synthetic pep-
ides derived from the entire Env, Gag, and Tax proteins (Fig. 1).
apping of CD8+ T cell epitopes was previously performed using
ymphocytes from mice, sheep and cattle [15,20,22,29]. Here, four
alves of the same age were experimentally infected with the same
mount of BLV taken from a single individual infected cow (Table 1).
n addition, the BoLA class I alleles of experimental calves were
etermined. According to the BoLA nomenclature committee of
he IPD–MHC database, calves A-JB and C-JB carried allele, BoLA-
*02604, B-JB carried allele, BoLA-N*02702,  and D-JB carried a novel
llele, BoLA-N*02701.  The proviral loads of infected calves were
stimated by BLV-CoCoMo-qPCR-2 [23–26]. These infected calves
ere proviral loads ranged from 72 to 76,839 copies per 105 cells
Table 1).
.2. Proliferation of CD8+ T cells from BLV-infected calves
CD8+ T cells were stimulated with the peptide pools that individ-
al peptide at 20 M and proliferations were measured by WST-8
ssay. APCs were prepared by the CD8+ T cell-depleted PBMCs that
reating with mitomycin C for 60 min  to inhibit cells proliferation.
ig. 2 shows that peptide pools 9, 10, 11, 13, 14, 15, and 21 induced
igher CD8+ T cell proliferation for calf A-JB; pools 8, 9, 11, 14, and
1 induced higher CD8+ T cell proliferation for calf B-JB; pools 9,
1, 14, 20, and 21 induced higher CD8+ T cell proliferation for calf
-JB; and pools 9, 13, 14, 15, and 21 induced higher CD8+ T cell
roliferation for calf D-JB.
To further map  the CD8+ T cell epitopes recognized by exper-
mental calves, CD8+ T cell proliferative responses to the each
eptide within positive peptide pools were examined in the
ig. 2. CD8+ T cell proliferative responses to 23 peptide pools. CD8+ T cells were separat
D)]  and used as effector cells. CD8− T cells were treated with 50 g/ml mitomycin C fo
ells  (1 × 105 cells/50 l) were treated with 80% DMSO (negative control) or with 23 pep
ncubation for 109 h at 37 ◦C, the CD8+ T cell proliferation responses were examined in a
ells.2015) 7194–7202 7197
WST-8 assay (Fig. 3). On this second screening, only two  pep-
tides, gp30N16 and gp51N11, induced particularly high CD8+ T cell
proliferation in calf A-JB, which had 72 copies BLV proviral load
per 105 cells (Fig. 3A). By contrast, the three other calves with
higher proviral loads than A-JB responded to a greater number of
peptides. In calf C-JB, which had 67,729 copies BLV proviral load
per 105 cells signiﬁcant CD8+ T cell proliferation was observed
in response to stimulated with ﬁve peptides (gp30N6, gp30N8,
gp51N11, gp51N12, and tax19) (Fig. 3C). Interestingly, calf D-JB
which proviral load was 76,839 copies per 105 cells, showed CD8+
T cell proliferative responses to the largest number (seven) of
peptides (gp30N6, gp51N5, gp51N11, gp51N12, tax16, tax18, and
tax20) (Fig. 3D). Peptides gp30N5, gp30N6, gp30N16, and gp51N11
increased the CD8+ T cell proliferation for calf B-JB, which proviral
load was  58,501 copies per 105 cells (Fig. 3B).
The number of CD8+ T cell epitopes was  correlated with the
proviral load in BLV-infected calves. In addition, all four calves
responded to peptide gp51N11, indicating that this peptide was the
strongest at inducing CD8+ T cell proliferation. Notably, no epitopes
were found from Gag structural proteins.
3.3. Non-radioactive cytotoxicity assay
To identify the immunodominant epitope, all 11 peptides that
induced a CD8+ T cell proliferative response were tested for their
ability to induce cytotoxicity. First, the optimal conditions for cyto-
toxicity assay were determined for using autologous PBMCs as
supplemental APCs, and the optimal ratio of effector cells and tar-
get cells was  determined as 10:1 for calf A-JB and 20:1 for the
other three calves when using 5 × 104 PBMCs per well (data not
shown).
Next, non-radioactive cytotoxicity assays were carried out by
incubating APCs with CD8+ T cells in the presence of different con-
centrations (0, 0.5, 5, or 20 M)  of peptides. Fig. 4A shows the
results obtained from calf A-JB, gp30N16 and gp51N11 induced
cytotoxic activity in a dose-dependent manner. By contrast, in calf
C-JB, all ﬁve peptides signiﬁcantly increased the CTL activity com-
pared to the negative control, but none displayed dose-dependent
ed from PBMCs from four BLV-infected calves [A-JB (A), B-JB (B), C-JB (C), and D-JB
r 60 min  at 37 ◦C and used as APCs. CD8+ T cells (1 × 105 cells/50 l) and CD8− T
tide pools, each containing ﬁve individual peptides at 20 M of each peptide. After
 WST-8 assay. The bars represent the mean ± standard deviation (S.D.) of triplicate
7198 L. Bai et al. / Vaccine 33 (2015) 7194–7202
Fig. 3. CD8+ T cell proliferative responses to individual peptides within positive peptide pools. CD8+ T cells (effector cells; 1 × 105 cells/50 l) from four BLV-infected calves
[A-JB  (A), B-JB (B), C-JB (C), and D-JB (D)] and CD8− T cells (APCs; 1 × 105 cells/50 l) were treated with mitomycin C and incubated with 80% DMSO (negative control) or
2  9, 11,
1 e CD8+
t
a
e
c
t0  M of each peptide from pools 9, 10, 11, 13, 14, 15, and 21 for calf A-JB, pools 8,
5,  and 21 for calf D-JB. The cells were treated with peptide for 109 h at 37 ◦C and th
he  mean ± standard deviation (S.D.) of triplicate wells.ctivity (Fig. 4C); a concentration of 0.5 M,  which was  the low-
st concentration tested for each peptide, induced near-maximal
ytotoxicity. In contrast to A-JB and C-JB, D-JB showed differing pat-
erns of CTL activity depending on the peptides (Fig. 4). However, 14, and 21 for calf B-JB, pools 9, 11, 14, 20, and 21 for calf C-JB, and pools 9, 13, 14,
T cell proliferation responses were examined in a WST-8 assay. The bars representCTL lysed target cells in response to gp51N11 only at the highest
concentration tested (20 M).  On the other hand, the tax16, tax18,
and tax20 peptides induced cytotoxicity in a dose-dependent man-
ner in D-JB, while gp51N12 had little effect. As shown in Fig. 4B,
L. Bai et al. / Vaccine 33 (2015) 7194–7202 7199
Fig. 4. Cytotoxic activity of CD8+ cytotoxic T cells against autologous PBMCs in response to peptides. These peptides had CD8+ T cell proliferative response in the WST-8 assay.
CD8+ T cells (effector cells, EC) were separated from PBMCs from four BLV-infected calves [A-JB (A), B-JB (B), C-JB (C), and D-JB (D)] and incubated with autologous PBMCs
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ftarget  cells, TC) with different concentrations of peptide (0, 0.5, 5, or 20 M),  and
ytotoxicity assay. A-JB was  tested at an EC:TC ratio of 10:1, while B-JB, C-JB, and D-
S.D.)  of triplicate wells. Signiﬁcant differences between the groups are indicated by
he gp30N16 peptide showed the cytotoxic activity in a dose-
ependent manner, reaching 80.9% and 77.9% cytotoxicity at 20 M
n calves B-JB and A-JB, respectively, while 0.5 M of each of the
ther three peptides was sufﬁcient to kill target cells in B-JB.
.4. Estimation of the Wu–Kabat variability index for positive
eptides
The conservation of amino acids in the 11 CD8+ CTL epitopes
as evaluated using the Wu–Kabat variability index. Fig. 5 shows
he Wu–Kabat variability indexs of the 11 CD8+ CTL epitopes based
n information on Env and Tax amino acid sequence variants
btained from the Genbank database. A value of 1 indicates that
n amino acid site is monomorphic, while a value of >2 indicates
 polymorphic site [28]. Interestingly, four residues of gp51N11
nd three residues of gp51N12 had values exceeding 4 that the
ighest variability values (Fig. 5A). By contrast, the other epitopes
f gp30 were slightly less polymorphic than the epitopes within
he gp51 (Fig. 5B). Particularly, the gp30N16 contains a proline-
ich region upstream of immunoreceptor tyrosine-based activation
otifs (ITAMs) and immunoreceptor tyrosine-based inhibition
otif (ITIMs) [30]. In addition, identiﬁed tax epitope region, which
nclude a leucine-rich activation domain that encompasses a trans-
riptional activation region [31], are less polymorphic (Fig. 5C).
ndeed, only one residue in each of epitopes gp30N5 and tax16 had
alues exceeding 4 (Fig. 5A and B).. Discussion
Here, we determined 11 novel CD8+ CTL epitopes and produced
our major conclusions. First, we found it interesting that this istotoxic activity of the CD8 T cells was  examined in a CytoTox96 non-radioactive
re used at an EC:TC ratio of 20:1. The bars represent the mean ± standard deviation
isks (*p < 0.05, **p < 0.01, and ***p < 0.001).
the ﬁrst time T cell epitopes from the gp30 have been identiﬁed.
In previous reports, some regions of gp51 and Tax were identiﬁed
as T cell and B cell epitopes [15,20,22,29], but so far no T cell or
B cell epitopes from gp30 have been reported. On the contrary,
no epitopes were found in Gag proteins. Second, fewer CD8+ CTL
epitopes were identiﬁed from calf A-JB with the low proviral load,
and more CD8+ CTL epitopes were identiﬁed from higher provi-
ral load than A-JB. This result strongly suggests that the number
of CD8+ T cell epitopes correlates with the proviral load in BLV-
infected cattle. Third, although several different CD8+ CTL epitopes
were identiﬁed from individual calf, a common CD8+ CTL epitope,
gp51N11, has capability of inducing cytotoxicity in all four calves.
Thus, the predominant CD8+ CTL epitope may be located in the cen-
tral portion of gp51. However, gp51N11 is not considered a suitable
target for a vaccine, because it shows high variability according to
the Wu–Kabat variability index. Fourth, Wu–Kabat variability index
analysis clearly showed that CD8+ CTL epitopes corresponding to
gp30 and Tax were less polymorphic than those of gp51. In addition,
CD8+ CTL epitopes from all experimental calves were derived from
the gp30 protein but not the Tax protein, indicating that the BLV
gp30 region may  be the best candidate for vaccine development.
The number of CD8+ T cell epitopes appeared to correlate with
the proviral load in BLV-infected cattle as evidence by: (i) The
number of peptides that induced good CD8+ T cells proliferation
increased with the BLV proviral load in the experimental calves;
(ii) Four epitopes on the Tax protein were detected in only two
cattle with viral loads of 67,729 and 76,839 copies per 105 cells.
This suggests that Tax-speciﬁc CTL may  be induced in animals with
higher (>58,501 copies per 105 cells) proviral loads because the
expression of Tax protein is very weak compared with the expres-
sion of the Env proteins; (iii) gp30N16-speciﬁc CTL was  only found
7200 L. Bai et al. / Vaccine 33 (2015) 7194–7202
Fig. 5. Wu–Kabat variability index of the CD8+ CTL epitopes on all sequences of gp51, gp30, and Tax. The 517 sequences of gp51, 118 sequences of gp30, and 90 sequences
of  Tax were obtained from the GenBank database. The vertical axis indicates the Wu–Kabat index at each amino acid position and the horizontal axis shows the amino acid
positions. (A) The Wu–Kabat index of the gp51 region (amino acids 1-301). Red, blue, and yellow blocks indicate the CD8+ CTL epitopes gp51N5, gp51N11, and gp51N12,
respectively. (B) The Wu–Kabat index of the gp30 region (amino acids 302–515). The blue, brown, green, and pink blocks indicate the CD8+ CTL epitopes gp30N5, gp30N6,
gp30N8, and gp30N16, respectively. (C) The Wu–Kabat index of Tax region (amino acids 1–309). The blue, red, green, and pink blocks indicate the CD8+ CTL epitopes tax16,
tax18,  tax19, and tax20, respectively. (D) The sequences and Wu–Kabat index at each position of the CD8+ CTL epitopes (For interpretation of the references to color in this
ﬁgure  legend, the reader is referred to the web  version of this article.).
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n the calves A-JB and B-JB. gp30N16 encompasses a proline-rich
egion upstream of the ITAMs and ITIMs of the cytoplasmic tail
f the envelope protein [30], which is known to be an SH3 bind-
ng site [32]. In addition, the down-regulatory phosphatase SHP-1
cts as a critical negative regulator of B-cell receptor signaling, and
p30 was thought be may  act as a decoy to sequester SHP-1, Thus,
p30N16 was thought maybe relevant in the context of T and B
ediated immunity [45]. Therefore, CTL targeting this domain may
e efﬁcient at eliminating BLV-infected cells by cytotoxic activity.
In another previous study, synthetic peptides corresponding to
he gp51 were used to test helper T cell epitopes, and peptide
8–117 was able to induce B cell neutralizing responses in mice
nd a particularly strong helper T cell response in BLV-infected
heep [15]. The 17 residues within gp51N11, which was  identi-
ed in this study, correspond to peptide 98–117. Fig. 4 clearly
llustrates that gp51N11 has cytotoxic activity on autologous BLV-
nfected cells from all four calves. The BoLA class I allele is highly
olymorphic [10,11]. Indeed, the major BoLA class I allele was dif-
erent in each of the four calves. The gp51N11 epitope may  contain
ecognition site that binds to one or more BoLA class I alleles.
eptides 169–188 and 177–192 of gp51 induce good proliferation
f bovine PBMCs depleted of B cells [14]. These peptides corre-
pond to 12 residues within gp51N17, full length gp51N18, and
2 residues within gp51N19. Another peptide derived from Env,
ep61, contains some sequences that induce T cell proliferation
r mitogenicity in mice [21]. This peptide corresponds closely to
p51N7, which did not show CD8+ T cell proliferative activity in this
tudy. Thus, the epitopes gp51N17–19 may  be signiﬁcant recogni-
ion sites in some cattle, but were not identiﬁed as such in the four
xperimental cattle in our study.
We identiﬁed four tax CD8+ CTL epitopes that correspond to the
egion approximately halfway between amino acids 151 and 210
f the BLV Tax protein. Interestingly, this region of Tax contains
 leucine-rich activation domain between residues 157 and 197
hat contains 24% of the protein’s leucine residues and is possibly
nvolved in heterologous protein interactions [31]. The leucine-rich
ctivation domain also encompasses a transcriptional activating
egion that plays an important role in viral replication [31]. In
ddition, these CD8+ CTL epitopes on the Tax protein have few poly-
orphic sites (Fig. 5C). Various studies showed that the HTLV Tax
rotein contains several CTL epitopes [33–38] and induces strong
TL responses against HTLV-1-infected patients [39–41]. These
esults suggest that the tax CD8+ CTL epitope may  be a potential
andidate for an anti-BLV vaccine.
By contrast, Sakakibara et al. reported that peptides of the BLV
ax protein at amino acids 111–130 and 131–150, and at 111–130
nd 261–280, are T cell epitopes and B cell epitopes for mice,
espectively [20]. These sequences of Tax corresponded to pep-
ides tax11–13, tax13–15, and tax 26–28 in our study, which did
ot induce CD8+ T cell proliferation. We  identiﬁed CD8+ CTL epi-
opes of Tax that induced high cytotoxic activity against autologous
LV-infected cells. The T cell epitopes that have been identiﬁed in
ice by Sakakibara et al. may  therefore not be CD8+ CTL epitopes
n cattle, indicating that there are differences in CD8+ CTL epitopes
etween mice and cattle.
The transmembrane protein gp30 is a glycosylated polypeptide
1,2] that can induce the fusion of viral and cellular membranes
n infected cells [42]. However, it was unclear whether CD8+ CTL
pitopes are present in the gp30. In this paper, four CD8+ CTL
pitopes were identiﬁed in gp30 for the ﬁrst time. In particular,
p30N16 showed strong cytotoxic activity in calves A-JB and B-JB,
espectively. In addition, the cytotoxic activity at 0.5 M of gp30N6
as 35.2–68.6% in calves B-JB, C-JB, and D-JB. Thus, CD8+ CTL epi-
opes from the gp30 were identiﬁed in all four BLV-infected calves,
egardless of proviral load. Interestingly, four epitopes from the
p30 were less polymorphic than the epitopes from the gp51. These2015) 7194–7202 7201
results indicate that the BLV gp30 region may be a useful target for
vaccines development.
Stability is an important factor for developing epitope-
driven vaccines. In previous study [46], the peptide 121-145 of
PPE68 (Rv3873) which was a major antigenic protein encoded
by Mycobacteriun tuberculosis-speciﬁc genomic region of dif-
ference 1 was identiﬁed by antigen-speciﬁc T-cell lines from
HLA-heteregeneous subjects, and conserved in all sequenced
strains/species of M. tuberculosis and M.  tuberculosis complex, and
several other pathogenic mycobacterial species; the peptide aa
121–145 was thought to be exploited as a peptide-based vaccine
candidate against tuberculosis and other mycobacterial diseases.
Therefore, we analyzed the conservation of amino acids in the
11 CD8+ CTL epitopes using the Wu–Kabat variability index. All
three epitopes from gp51 showed signiﬁcantly higher variability
than epitopes from gp30 and Tax. In particular, gp51N11 which
induced responses in four all experimental calves, had the highest
Wu–Kabat variability value. The epitope gp51N12 showed a sim-
ilar pattern as gp51N11, in that it induced cytotoxic activity on
autologous BLV-infected cells and had a high Wu–Kabat variability
value. These data indicate that gp51N11 and gp51N12 are more
variable at amino acid positions 141 and 155, respectively. The
gp51 mediates binding of virions to cell surface receptors [42], and
induces the expression of speciﬁc antibodies in infected animals
[1]. Variability within the gp51N11 and gp51N12 epitopes allow for
efﬁcient modiﬁcation of host immune responses. Although many
vaccine trials have been undertaken [43], an effective vaccine has
yet not been developed against BLV maybe because vaccine strate-
gies have focused on the Env protein gp51. In contrast to gp51,
epitopes derived from gp30 and Tax are less polymorphic. These
results provide useful information for BLV vaccines development.
5. Conclusions
Eleven novel CD8+ CTL epitopes were identiﬁed. However, no
CD8+ CTL epitopes were found from the Gag proteins. Interestingly,
several epitopes were obtained from Tax and gp30, indicating that
cellular immunity against BLV is strongly targeted to these proteins.
Tax protein has a few polymorphic sites, but tax epitopes just were
identiﬁed in two  calves. At least one epitope from gp30 region was
identiﬁed in all four calves, and these epitopes have high conserva-
tion than epitopes of gp51. Although CTL epitopes were identiﬁed
from the gp51, they have high variability and therefore not a suit-
able target for designing a vaccine. These results show that the gp30
region may  be the best candidate for BLV vaccine development.
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